Live Quote · NASDAQRYTMHealthcare · Biotechnology

Rhythm Pharmaceuticals, Inc.

$114.17▲ 3.41%(+$3.76)

TickerSpark Score

63/100

▌ Mixed

25

Valuation

40

Profitability

100

Growth

72

Health

80

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RYTM research report →

52-Week Range86% of range

Low

$64.65

Current

$114.17

High

$122.20

Company Overviewwww.rhythmtx.com

About the company

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R).

CEO: David Meeker
IPO: 2017
Employees: 283
HQ: Boston, MA, US

Price Chart

+70.61% · this period

Valuation

Market Cap: $7.83B
P/E: -36.48
P/S: 36.06
P/B: 63.14
EV/EBITDA: -44.24
Div Yield: 0.00%

Profitability

Gross Margin: 89.41%
Op Margin: -90.89%
Net Margin: -93.33%
ROE: -203.25%
ROIC: -56.40%

Growth & Income

Revenue: $189.76M · 45.83%
Net Income: $-196,539,000 · 24.58%
EPS: $-3.11 · 28.34%
Op Income: $-192,016,000
FCF YoY: -2.41%

Performance & Tape

52W High: $122.20
52W Low: $64.65
50D MA: $92.30
200D MA: $98.16
Beta: 1.88
Avg Volume: 799.32K

Get TickerSpark's AI analysis on RYTM

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
Jul 1, 26	Garfield Alastair	officer: Chief Scientific Officer	other	4,445	$0
Jul 1, 26	Garfield Alastair	officer: Chief Scientific Officer	other	2,150	$237.38K
Jul 1, 26	Garfield Alastair	officer: Chief Scientific Officer	other	4,445	$0
Jun 23, 26	JEAN CHRISTOPHE	director	other	4,712	$0
Jun 24, 26	JEAN CHRISTOPHE	director	other	3,691	$396.97K
Jun 24, 26	JEAN CHRISTOPHE	director	other	2,324	$0
Jun 23, 26	JEAN CHRISTOPHE	director	other	4,712	$0
Jun 23, 26	MCGIRR DAVID W J	director	other	4,712	$0
Jun 24, 26	MCGIRR DAVID W J	director	other	3,691	$396.97K
Jun 24, 26	MCGIRR DAVID W J	director	other	2,324	$0

Coverage · RYTM

Our RYTM coverage

Recent articles, reports, and earnings notes.

View all →

IPO

Should You Buy the Palatin Technologies IPO? Here's the Setup

Palatin Technologies, Inc. (NASDAQ: PTN) is expected to list on May 29, 2026, but the price range has not been disclosed. The company is not a traditional IPO: it is a long-public biotech moving to Nasdaq via a resale registration tied to warrant exercises. The bull case is pipeline leverage in obesity and rare disease; the bear case is dilution, losses, and a very tight cash position.